drugset
drugset / Trial / NCT06544551

Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection

NCT06544551 ↗

Phase 3 Completed 336 enrolled Beijing Kawin Technology Share-Holding Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Current clinical practices has shown promising prospects of the therapy strategy of interferon combined with nucleos(t)ides in patients with chronic hepatitis B, but the safety and efficacy has not been fully studied. This study is aimed to exploit the safety and efficacy of the study drug, Peginterferon Alfacon-2 injection, with nucleos(t)ide (NAs), Tenofovir alafenamide Fumarate Tablets (TAF), in the patients with hepatitis B virus infection.

Timeline

Start
2021-12-28
Primary completion
2023-11-30
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon Alfacon-2 Protein / enzyme biologic — Subcutaneous
Background tenofovir alafenamide Small molecule — Oral

Indications

chronic hepatitis B virus infection